WHWK - NASDAQ
Whitehawk Therapeutics Inc
$4.40
+2.6%Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
At a Glance
Live Snapshotwhwk
Research Development Expenses
Last Annual Value
90.96M
3-Year CAGR
41%
5-Year CAGR
43%
10-Year CAGR
23%
Whitehawk Therapeutics Inc Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Whitehawk Therapeutics Inc NASDAQ:WHWK | 90.96M | 23.0% | 35.8% | N/A | |
 Ovid Therapeutics Inc. NASDAQ:OVID | 25.58M | -3.6% | -11.4% | 10.3% | |
 Context Therapeutics Inc. NASDAQ:CNTX | 31.86M | 21.5% | 53.0% | N/A | |
 Adverum Biotechnologies, Inc. NASDAQ:ADVM | 77.04M | -0.2% | -2.9% | 9.3% | |
 aTyr Pharma, Inc. NASDAQ:ATYR | 60.22M | 12.5% | 21.0% | 3.1% | |
 Biomea Fusion, Inc. NASDAQ:BMEA | 61.98M | -15.5% | 17.2% | N/A | |
 Fractyl Health, Inc. Common Stock NASDAQ:GUTS | 74.54M | 25.1% | 23.0% | N/A | |
 Kalaris Therapeutics Inc NASDAQ:KLRS | 30.75M | 38.0% | -23.8% | N/A | |
 Oramed Pharmaceuticals Inc. NASDAQ:ORMP | 6.38M | -10.7% | -21.2% | -1.9% | |
 Quince Therapeutics, Inc. NASDAQ:QNCX | 18.59M | 25.3% | -21.1% | N/A | |
 Spruce Biosciences, Inc. NASDAQ:SPRB | 19.52M | -26.6% | -8.7% | N/A |
Whitehawk Therapeutics Inc Fair Value Envelope
Related Guides
Continue your WHWK research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.